午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

CLEC2D抗體,Rabbit Polyclonal CLEC2D Antibody
  • CLEC2D抗體,Rabbit Polyclonal CLEC2D Antibody
  • CLEC2D抗體,Rabbit Polyclonal CLEC2D Antibody

CLEC2D抗體 新品

價(jià)格 詢價(jià)
包裝 20μl 50μl 100μl
最小起訂量 1μl
發(fā)貨地 湖北
更新日期 2025-05-12
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:CLEC2D抗體英文名稱:Rabbit Polyclonal CLEC2D Antibody
品牌: 艾普蒂產(chǎn)地: 武漢
保存條件: Stored at -20°C for 3424 year. Avoid repeated freeze / thaw cycles.產(chǎn)品類別: 抗體
重組: 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat 宿主: Rabbit
偶聯(lián)物: 靶點(diǎn): CLEC2D
2025-05-12 CLEC2D抗體 Rabbit Polyclonal CLEC2D Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武漢 Stored at -20°C for 3424 year. Avoid repeated freeze / thaw cycles. 抗體

驗(yàn)證與應(yīng)用

應(yīng)用及物種
WB咨詢技術(shù) Human,Mouse,Rat
IF咨詢技術(shù) Human,Mouse,Rat
IHC1/50-1/200 Human,Mouse,Rat
ICC技術(shù)咨詢 Human,Mouse,Rat
FCM咨詢技術(shù) Human,Mouse,Rat
Elisa1/1000-1/5000 Human,Mouse,Rat
   

產(chǎn)品詳情

AliasesTHBD; TM; THRM; AHUS6; BDCA3; THPH12
Entrez GeneID7056
clone2C6C3
WB Predicted band size60.3kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD141 (AA: extra 297-505) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of HL-60 cells using CD141 mouse mAb (green) and negative control (red).    


           

參考文獻(xiàn)

1. **"CLEC2D Functions as a Novel Co-Stimulatory Receptor on Human CD8+ T Cells"**

*Authors: Smith A, et al.*

摘要:探討CLEC2D在CD8+ T細(xì)胞中的共刺激作用,發(fā)現(xiàn)其抗體可增強(qiáng)T細(xì)胞抗腫瘤活性,為免疫治療提供新靶點(diǎn)。

2. **"Structural and Functional Characterization of the CLEC2D-Ligand Interaction"**

*Authors: Tanaka K, et al.*

摘要:解析CLEC2D蛋白結(jié)構(gòu)及與其配體結(jié)合機(jī)制,開發(fā)特異性抗體阻斷信號(hào)通路,揭示其在炎癥反應(yīng)中的調(diào)控作用。

3. **"CLEC2D Expression Correlates with Immune Evasion in Hepatocellular Carcinoma"**

*Authors: Li Y, et al.*

摘要:分析CLEC2D在肝癌組織中的高表達(dá)與免疫抑制微環(huán)境的關(guān)系,抗體阻斷實(shí)驗(yàn)顯示可恢復(fù)NK細(xì)胞殺傷功能。

4. **"CLEC2D Modulates Viral Infection by Regulating Dendritic Cell Maturation"**

*Authors: Garcia-Beltran W, et al.*

摘要:研究CLEC2D抗體對(duì)樹突狀細(xì)胞功能的調(diào)控,發(fā)現(xiàn)其通過抑制CLEC2D可增強(qiáng)抗病毒免疫應(yīng)答。

(注:以上文獻(xiàn)為示例,實(shí)際引用需根據(jù)真實(shí)研究調(diào)整。)

       

背景信息

CLEC2D (C-type lectin domain family 2 member D) is a transmembrane protein belonging to the C-type lectin receptor family, primarily expressed on immune cells such as natural killer (NK) cells, γδ T cells, and subsets of CD8+ T cells. It plays a role in immune regulation by interacting with ligands like LLT1 (CLEC2D’s canonical ligand) or other cell-surface molecules, modulating cytotoxic activity and cytokine production. CLEC2D contains an extracellular C-type lectin-like domain and an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM), suggesting its involvement in inhibitory signaling pathways. Dysregulation of CLEC2D has been implicated in diseases such as cancer, autoimmune disorders, and viral infections, where it may either suppress anti-tumor immunity or contribute to immune tolerance.

Antibodies targeting CLEC2D are research tools or potential therapeutics designed to block or modulate its interactions. For example, antagonistic antibodies may enhance NK cell-mediated cytotoxicity by disrupting CLEC2D-LLT1 binding, thereby counteracting immune suppression in tumors. Conversely, agonistic antibodies might exploit CLEC2D’s inhibitory signals to dampen excessive inflammation in autoimmune conditions. Current studies focus on characterizing CLEC2D’s ligand specificity, tissue distribution, and downstream signaling to refine antibody design. Challenges include ensuring specificity and minimizing off-target effects due to structural similarities among C-type lectin family members. Preclinical models are evaluating CLEC2D antibodies for efficacy in cancer immunotherapy and immune modulation, highlighting its dual role as a checkpoint molecule. Further research aims to optimize antibody affinity, isotype selection, and combination therapies for clinical translation.

       
關(guān)鍵字: CLEC2D抗體;CLEC2D;CLEC2D Antibody;

公司簡介

湖北瑞和寧生物科技有限公司研究創(chuàng)新能力, 擁有完整、科學(xué)、質(zhì)量管理體系。并不斷致力于技術(shù)創(chuàng)新,產(chǎn)品創(chuàng)新和管理創(chuàng)新,贏得了國內(nèi)外廣大用戶的信任。
成立日期 2024-06-24 (2年) 注冊(cè)資本 50萬(元)
員工人數(shù) 1-10人 年?duì)I業(yè)額 ¥ 100萬以內(nèi)
主營行業(yè) 中間體,化學(xué)試劑 經(jīng)營模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 湖北瑞和寧生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注冊(cè)資本:50萬(元)
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營產(chǎn)品:中間體。試劑
  • 公司地址:江漢區(qū)
詢盤

店內(nèi)推薦

PKD2抗體 詢價(jià)
SCN5A抗體 詢價(jià)
MUC3A抗體 詢價(jià)

CLEC2D抗體相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
¥1950
VIP3年
上海滬震實(shí)業(yè)有限公司
2025-08-01
詢價(jià)
VIP1年
鄭州赫昂生物科技有限公司
2025-06-03
¥1800
南京安研生物科技有限公司
2024-05-27
詢價(jià)
VIP1年
上海切爾齊生物科技有限公司
2025-05-19
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁 | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.